利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

51 条记录 (耗时 0.032 秒)

    Modified Coagulation Factor VIIa With Extended Half-Life
    4.
    发明申请
    Modified Coagulation Factor VIIa With Extended Half-Life 有权
    具有延长半衰期的改性凝血因子VIIa

    公开(公告)号：US20090298760A1

    公开(公告)日：2009-12-03

    申请号：US12223616

    申请日：2007-02-03

    申请人： Thomas Weimer ,  Stefan Schulte ,  Ulrich Kronthaler ,  Wiegand Lang ,  Uwe Liebing ,  Wilfried Wormsbächer

    发明人： Thomas Weimer ,  Stefan Schulte ,  Ulrich Kronthaler ,  Wiegand Lang ,  Uwe Liebing ,  Wilfried Wormsbächer

    IPC分类号： A61K38/38 ,  C12P21/04 ,  C12N5/00 ,  C12N15/63 ,  A61K31/7088 ,  C07K14/76 ,  C07H21/04

    CPC分类号： A61K38/4846 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/385 ,  C07K14/76 ,  C07K2319/00 ,  C07K2319/31 ,  C12N9/6437 ,  C12N9/96 ,  C12N15/62 ,  C12Y304/21021

    摘要： The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.

    摘要翻译： 本发明涉及因子VII（FVII）和因子VIIa（FVIIa）白蛋白连接多肽的领域。 更具体地，本发明涉及编码人因子VII和因子VIIa的cDNA序列和与编码人血清白蛋白的cDNA遗传融合的衍生物，其可以通过寡核苷酸连接，所述寡核苷酸编码干扰肽接头，这种编码的衍生物表现出改进的稳定性和延长的功能 血浆半衰期，含有这些cDNA序列的重组表达载体，用这种重组表达载体转化的宿主细胞，确实具有未修饰的野生型蛋白的生物活性但具有改善的稳定性和延长的保存期限的重组多肽和衍生物 制备这些重组蛋白及其衍生物。 本发明还涵盖用于人基因治疗的转移载体，其包含这种修饰的DNA序列。

    Modified coagulation factor VIIa with extended half-life
    5.
    发明授权
    Modified coagulation factor VIIa with extended half-life 有权
    改性凝血因子Ⅶa具有延长的半衰期

    公开(公告)号：US08765915B2

    公开(公告)日：2014-07-01

    申请号：US12223616

    申请日：2007-02-03

    申请人： Thomas Weimer ,  Stefan Schulte ,  Ulrich Kronthaler ,  Wiegand Lang ,  Uwe Liebing ,  Wilfried Wormsbächer

    发明人： Thomas Weimer ,  Stefan Schulte ,  Ulrich Kronthaler ,  Wiegand Lang ,  Uwe Liebing ,  Wilfried Wormsbächer

    IPC分类号： A61K38/35 ,  A61K38/38 ,  C07K14/745 ,  C07K14/76 ,  C07K14/765 ,  C12N9/64 ,  A61K38/00

    CPC分类号： A61K38/4846 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/385 ,  C07K14/76 ,  C07K2319/00 ,  C07K2319/31 ,  C12N9/6437 ,  C12N9/96 ,  C12N15/62 ,  C12Y304/21021

    摘要： The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.

    摘要翻译： 本发明涉及因子VII（FVII）和因子VIIa（FVIIa）白蛋白连接多肽的领域。 更具体地，本发明涉及编码人因子VII和因子VIIa的cDNA序列和与编码人血清白蛋白的cDNA遗传融合的衍生物，其可以通过寡核苷酸连接，所述寡核苷酸编码干扰肽接头，这种编码的衍生物表现出改进的稳定性和延长的功能 血浆半衰期，含有这些cDNA序列的重组表达载体，用这种重组表达载体转化的宿主细胞，确实具有未修饰的野生型蛋白的生物活性但具有改善的稳定性和延长的保存期限的重组多肽和衍生物 制备这些重组蛋白及其衍生物。 本发明还涵盖用于人基因治疗的转移载体，其包含这种修饰的DNA序列。

    Method of measuring a deviation of an optical surface from a target shape using interferometric measurement results
    7.
    发明授权
    Method of measuring a deviation of an optical surface from a target shape using interferometric measurement results 有权
    使用干涉测量结果测量光学表面与目标形状的偏差的方法

    公开(公告)号：US08508749B2

    公开(公告)日：2013-08-13

    申请号：US13609084

    申请日：2012-09-10

    申请人： Ralf Arnold ,  Stefan Schulte ,  Bernd Doerband

    发明人： Ralf Arnold ,  Stefan Schulte ,  Bernd Doerband

    IPC分类号： G01B11/02

    CPC分类号： G01B9/021 ,  G01B9/02039 ,  G01B11/2441 ,  G01M11/025 ,  G01M11/0271 ,  Y10T29/49771

    摘要： A method of measuring a deviation of an optical surface from a target shape and a method of manufacturing an optical element. This method of measuring the deviation includes: performing a first interferometric measurement using a first diffractive measurement structure, which is arranged to cover a first area of the optical surface, to provide a first interferometric measurement result, performing a second interferometric measurement using a second diffractive measurement structure, which is arranged to cover a second area of the optical surface different from the first area, to provide a second interferometric measurement result, and determining a deviation of the optical surface from the target shape.

    摘要翻译： 测量光学表面与目标形状的偏差的方法和制造光学元件的方法。 这种测量偏差的方法包括：使用被布置成覆盖光学表面的第一区域的第一衍射测量结构来执行第一干涉测量，以提供第一干涉测量结果，使用第二衍射进行第二干涉测量 测量结构被布置成覆盖与第一区域不同的光学表面的第二区域，以提供第二干涉测量结果，以及确定光学表面与目标形状的偏差。

    METHOD OF MEASURING A DEVIATION OF AN OPTICAL SURFACE FROM A TARGET SHAPE
    8.
    发明申请
    METHOD OF MEASURING A DEVIATION OF AN OPTICAL SURFACE FROM A TARGET SHAPE 有权
    测量目标形状的光学表面偏差的方法

    公开(公告)号：US20100177320A1

    公开(公告)日：2010-07-15

    申请号：US12684600

    申请日：2010-01-08

    申请人： Ralf Arnold ,  Stefan Schulte ,  Bernd Doerband

    发明人： Ralf Arnold ,  Stefan Schulte ,  Bernd Doerband

    IPC分类号： G01B11/02 ,  G02B13/18

    CPC分类号： G01B9/021 ,  G01B9/02039 ,  G01B11/2441 ,  G01M11/025 ,  G01M11/0271 ,  Y10T29/49771

    摘要： A method of aligning at least two wave shaping elements, a method of measuring a deviation of an optical surface from a target shape and a measuring apparatus for interferometrically measuring a deviation of an optical surface from a target shape. The method of aligning at least two wave shaping elements, each of which wave shaping elements has a diffractive measurement structure for adapting part of a wave front of incoming light to a respective portion of the target shape, includes: providing a first one of the wave shaping elements with a diffractive alignment structure, arranging the wave shaping elements relative to each other such that each of the diffractive measurement structures is traversed by a separate subset of rays of the incoming light during operation of the measuring apparatus, and aligning the first wave shaping element and a second one of the wave shaping elements relative to each other by evaluating alignment light having consecutively interacted with the diffractive alignment structure and with the second wave shaping element.

    摘要翻译： 对准至少两个波形整形元件的方法，测量光学表面与目标形状的偏差的方法和用于干涉测量光学表面与目标形状的偏差的测量装置。 对准至少两个波形整形元件的方法，其中每个波形整形元件具有衍射测量结构，用于将入射光的一部分波前适应到目标形状的相应部分，包括：提供第一波 具有衍射对准结构的成形元件，将波形整形元件相对于彼此布置，使得每个衍射测量结构在测量设备的操作期间被入射光的单独的子集子穿过，并且对准第一波形整形 元件和第二波形成形元件相对于彼此，通过评估与衍射对准结构和第二波形整形元件连续相互作用的对准光。

    MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE
    9.
    发明申请
    MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE 有权
    改良的凝血因子与生殖健康生活息息相关

    公开(公告)号：US20100120664A1

    公开(公告)日：2010-05-13

    申请号：US12520840

    申请日：2007-12-21

    申请人： Stefan Schulte ,  Thomas Weimer ,  Hubert Metzner

    发明人： Stefan Schulte ,  Thomas Weimer ,  Hubert Metzner

    IPC分类号： A61K38/16 ,  C07K14/745 ,  C07K14/755 ,  C07H21/00 ,  C12N15/74 ,  C12N5/10 ,  C12P21/00 ,  A61P7/04

    CPC分类号： C07K14/755 ,  C07K14/745 ,  C07K14/765 ,  C07K16/18 ,  C07K2319/31

    摘要： The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.

    摘要翻译： 本发明涉及编码改性凝血因子，优选凝血因子VIII及其衍生物的核酸序列; 含有该核酸序列的重组表达载体; 用这些重组表达载体转化的宿主细胞; 和由所述核酸序列编码的重组多肽和衍生物，其中与未修饰的野生型蛋白相比，所述重组多肽和衍生物具有生物学活性和延长的体内半衰期。 本发明还涉及导致体外稳定性改善的相应序列。 本发明还涉及制备这些重组蛋白及其衍生物的方法。 本发明还涉及用于人基因治疗的转移载体，其包含这样的核酸序列。

    Fibrinogen purification
    10.
    发明授权
    Fibrinogen purification 有权
    纤维蛋白原净化

    公开(公告)号：US07550567B2

    公开(公告)日：2009-06-23

    申请号：US11062432

    申请日：2005-02-23

    申请人： Hubert Metzner ,  Uwe Liebing ,  Annette Feussner ,  Joerg Lemmer ,  Stefan Schulte ,  Volker Gawantka

    发明人： Hubert Metzner ,  Uwe Liebing ,  Annette Feussner ,  Joerg Lemmer ,  Stefan Schulte ,  Volker Gawantka

    IPC分类号： C07K14/75 ,  C07K1/16

    CPC分类号： C07K14/75

    摘要： The present invention relates to a process for purifying fibrinogen, which comprises one or more process steps in which one or more contaminating proteins are depleted by negative chromatography and/or negative adsorption using cation exchanger, hydrophobic gel and/or dye gel. In addition, the invention relates to the fibrinogen which is obtained by the process of the invention and which is notable for improved stability, and to the production and use of pharmaceutical preparations comprising this fibrinogen.

    摘要翻译： 本发明涉及一种用于纯化纤维蛋白原的方法，其包括一个或多个工艺步骤，其中一种或多种污染蛋白质通过阴离子色谱法和/或使用阳离子交换剂，疏水性凝胶和/或染料凝胶的负吸附来消耗。 此外，本发明涉及通过本发明的方法获得并且其显着改进的稳定性的纤维蛋白原以及包含该纤维蛋白原的药物制剂的生产和使用。